(Q36750148)

16 August 2017

1 reference

title

Transdermal rotigotine: a new non-ergot dopamine agonist for the treatment of Parkinson's disease (English)

1 reference

16 August 2017

1 reference

2

K Ray Chaudhuri

1 reference

16 August 2017

Y Naidu

1

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 March 2007

1 reference

Expert Opinion on Drug Delivery

16 August 2017

published in

1 reference

16 August 2017

volume

4

1 reference

16 August 2017

issue

2

1 reference

16 August 2017

page(s)

111-118

1 reference

Parkinsonism: onset, progression, and mortality

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17425247.4.2.111

Non-motor symptoms of Parkinson's disease: diagnosis and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.4.2.111

An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.4.2.111

Success and problems of long-term levodopa therapy in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.4.2.111

Clinical-pathological study of levodopa complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.4.2.111

Treatment interventions for Parkinson's disease: an evidence based assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.4.2.111

Continuous dopamine-receptor stimulation in early Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.4.2.111

Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.4.2.111

Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.4.2.111

Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.4.2.111

Transdermal delivery of dopaminergic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.4.2.111

A novel dopamine agonist for the transdermal treatment of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.4.2.111

Clinical studies with transdermal rotigotine in early Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.4.2.111

Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.4.2.111

Fibrotic valvular heart disease is not related to chemical class but to biological function: 5-HT2B receptor activation plays crucial role

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.4.2.111

Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.4.2.111

A serotonin 5-HT1A receptor agonist prevents behavioral sensitization to L-DOPA in a rodent model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.4.2.111

Treatment with alpha2-adrenoceptor antagonist, 2-methoxy idazoxan, protects 6-hydroxydopamine-induced Parkinsonian symptoms in rats: neurochemical and behavioral evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.4.2.111

A controlled trial of rotigotine monotherapy in early Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.4.2.111

Patch application of the dopamine agonist rotigotine to patients with moderate to advanced stages of restless legs syndrome: a double-blind, placebo-controlled pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.4.2.111

21 January 2018

Identifiers

DOI

10.1517/17425247.4.2.111

1 reference

16 August 2017

1 reference